Alan Lewis

Dr. Alan Lewis currently serves as an advisor to biotech companies. He has served as President, CEO and Director of Ambit Biosciences, a privately-held biotech company. He has also served as President and CEO of the Juvenile Diabetes Research Foundation (JDRF) and Novocell (ViaCyte). Prior to joining Novocell, was President of Celgene’s Signal Research, a wholly-owned subsidiary of the Celgene Corporation. He was President, CEO, and Director of Signal Pharmaceuticals, where he guided the company to its successful acquisition by Celgene. He previously was Vice President of Research at Wyeth. Dr. Lewis completed a postdoctoral fellowship at Yale University after obtaining a Ph.D. in pharmacology from the University of Wales in Cardiff. Dr. Lewis serves as a director on the boards of Biomarin, Ctyochroma, and Biotica.